SARS-CoV-2 vaccines and donor recruitment for FMT

Due to its clear benefits in the management of recurrent Clostridioides difficile infection, faecal microbiota transplantation (FMT) has been advocated by gastroenterological community as a non-postponable procedure be continuously delivered during COVID-19 pandemic.1Ianiro G Mullish BH Kelly CR et al.Screening transplant donors outbreak: suggestions for urgent updates from an international expert panel.Lancet Gastroenterol Hepatol. 2020; 5: 430-432Summary Full Text PDF PubMed Scopus (96) Google Scholar Therefore, specific recommendations have released reorganise workflow FMT pandemic avoid potential risk transmission severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through or donor–recipient transfer.2Xiao F Tang M Zheng X Liu Y Li Shan H Evidence gastrointestinal infection SARS-CoV-2.Gastroenterology. 158: 1831-1833Summary (1807) Briefly, these included use remote assessment patients and whenever possible, expansion donor screening with questionnaires laboratory testing aimed at excluding SARS-CoV-2 application safety measures endoscopic procedure.1Ianiro Scholar, 3Ianiro al.Reorganisation services pandemic.Gut. 69: 1555-1563Crossref (93) The vaccination campaign started worldwide past few weeks. One major category vaccines (developed both BioNTech Pfizer, also Moderna National Institute Allergy Infectious Diseases) is based on mRNA products that encode genetically modified spike protein. These are promising, 93–95% efficacy minimal side-effects. An additional emerging class vaccines, uses non-replicating adenovirus vector protein, including ChAdOx1 nCoV-19 University Oxford AstraZeneca vaccine, given least temporary authorisation some countries (eg, Argentina, Brazil, UK, among others). Finally, various vaccine technologies, live attenuated being investigated. Overall, efforts expected give considerable boost fight against COVID-19. Consequently, important discussion field human tissue transfer required, specifically FMT. We must consider what effect will clinical practice current knowledge data. first question whether there should waiting period between screening. In our latest consensus report stool biobanking, recent history (<2 months) virus was exclusion criteria case possible transmission.4Cammarota Ianiro al.International conference banking practice.Gut. 2019; 68: 2111-2121Crossref (218) For technologies (rather than virus), it does not seem feasible would transmission, this criterion can disregarded, already suggested blood donors.5EUR-LexCommission Directive 2004/33/EC 22 March 2004 implementing 2002/98/EC European Parliament Council regards certain technical requirements components.https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32004L0033Date: 2015Date accessed: January 14, 2021Google Nonetheless, available associated adverse events, fatigue, nausea, fever, headache, myalgia, arthralgia, pain injection site, others, which last several days after vaccination. As symptoms overlap those assessed (at entry questionnaire day each donation), might pragmatic wait 7–10 before evaluating inappropriate rejection candidates. It could reasonable follow such approach viral vectors, UK donation guidelines.6NHS Blood TransplantCoronavirus: advice.https://www.blood.co.uk/news-and-campaigns/news-and-statements/coronavirus-covid-19-updates/Date: 2020Date Live developed become use, but we still do data candidate vaccines. safest adhere guidelines type months screening.4Cammarota At initial evaluation, all candidates asked about and, if vaccinated, window time (the length depending vaccine) elapse moving forward full (appendix). Another who vaccinated require investigations Although recognised effective preventing COVID-19, uncertainty remains regarding their virus. More specifically, no presence faeces individuals exposed, faecal–oral yet know how long immunity lasts, difficult predict duration donor's protection open questions prevent any recommendation change streamline indications donors, assure us satisfactory level Irrespective above considerations, because different steps process evaluation patients, manipulation faeces, itself, follow-up patients) expose physicians wise strongly encourage conclusion, although roll-out turning point pandemic, alert applied cannot reduced until further emerges. AG reports personal fees consultancy Eisai Srl, 3PSolutions, Real Time Meeting, Fondazione Istituto Danone, Sinergie Sanofi; acting speaker Takeda, AbbVie, Sandoz; advisory boards VSL3 Eisai. BHM Finch Therapeutics. CRK served advisor, financial compensation, OpenBiome since 2013; she local principal investigator PRISM-3 trial, her institution receives salary support research coordinator compensation Therapeutics patient enrolled. FZ grants non-profit China Microbiota Transplantation System (fmtBank) patent GenFMTer separating issued Medical. GC received advisor Ferring GI Biocodex, Metagenics, consultant Therapeutics, Giuliani, Metagenics. HS Enterome, Roche, Amgen, BiomX, Ferring, Bristol Myers Squibb, Astellas, MSD, Novartis, Tillotts Pharma, Biose; BiomX; co-founder Exeliom Biosciences. JK EJK Vedanta JRA non-financial relationship scientific advisor. MF Rebiotix, Janssen. SCN Janssen, Pharma. SPC Janssen Shire, Microbiotica, Pfizer. ZK employee shareholder unpaid special OpenBiome. All other authors declare competing interests. Download .pdf (.08 MB) Help pdf files Supplementary appendix Screening panelAs outbreak disease 2019 (COVID-19), caused (SARS-CoV-2), rapidly spread countries, governments medical taking common sense radical quarantine measures.1 Full-Text